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b The ratio of plasmid retention for growth in nutrient starvation (NS) relative to standard medium (7H9), also calculated on a log 10 -scale and reported as arithmetic-scale mean and one standard deviation range.
c P-value for one-sided t-test of greater retention of plasmid in NS vs. 7H9. 
SUPPLEMENTARY METHOD TEXT:
A detailed description of the high-throughput compound screen
Preparation of assay-ready plates
The screening library consisted of circa 2 million unique compounds with a minimum of 90% purity.
Assay-ready plates were prepared by dispensing 60 nL of compound solutions in DMSO (1mM for single-concentration screening or 11-point serial dilutions down from 10mM in 1/3 steps) into black 1536-well flat bottom polystyrene plates (Greiner Bio-One Ltd., Stonehouse, UK) using an Echo 555 acoustic dispenser (Labcyte, Sunnyvale, CA). This gave a final compound concentration of 10 μM in a 6 μL final assay volume. In order to enable robust data normalization, each screening plate contained 64 negative (columns 11 and 12) and 64 positive (columns 35 and 36) control wells, which received 60 nL of
DMSO (1% v/v final concentration).

HPLC-based assay of enzyme activity
This assay was based on the incubation of Mtb Rel Mtb with adenosine 5'-triphosphate (ATP) and guanosine 5'-triphosphate (GTP), following the subsequent formation of adenosine 5'-monophosphate (AMP) by reverse-phase HPLC using ultraviolet absorbance detection. Separations were accomplished on a Zorbax Eclipse XDB C18 (4.6 x 150 mm, 5 µm) (Agilent) with a C18 Eclipse pre-column (12.5 x 4.6 mm, 5 µm) (Agilent). The mobile phase was delivered at a constant flow rate of 1.0 mL/min and the eluent was monitored continuously using a diode array detector set at 254 nm. The reaction mixture was eluted with potassium phosphate buffer (50 mM at pH 6) for 2 min; then the mobile phase gradient was increased linearly up to 12.5% methanol over 8 min and maintained at 12.5% methanol for 2 min. This method provided good chromatographic resolution and gave retention times of 1.9 min, 3.4 min, and 6.2 min for GTP, ATP, and AMP, respectively. The lower limit of quantification based on peak area was 5 µM for AMP (r 2 = 0.99).
Reactions were run at room temperature in a 200-µL volume, which contained a mixture of substrates and enzyme, in a 50 mM Tris buffer (pH 8.5) containing MgCl 2 at half-substrate concentration, 0.5 mM DTT and 1.5 mM deoxycholic acid. After incubation at room temperature, the reaction was terminated by addition of EDTA. Then, the solution was centrifuged (3500 rpm, 2 min at 4 ºC) and a 20 μL aliquot of the sample was injected for analysis.
The 
Enzyme inhibition screen
Buffer content plays a critical role in assay robustness. We optimized buffer source and pH (6.5-9.0) and also the effect of ionic strength, divalent cations, reducing agents, bovine serum albumin, detergents and polyols. When performing enzyme titration and progression curves, enzyme concentration was varied from 0 nM to 320 nM in the presence of 1.5 mM ATP, 0.5 mM GTP and 1 mM MgCl 2 . The reaction was stopped by EDTA addition at different times (0-120 min) at room temperature.
Before assay miniaturization, assays were performed in 384-well plates with 10 μL as final reaction volume using 1.5 mM ATP, 0.5 mM GTP, 1 mM MgCl 2, 4.5 nM AMP-Alexa 633 and 40 nM M.
tuberculosis RelMtb in 50 mM Tris (pH 8.5) containing 0.5 mM DTT and 1.5 mM deoxycholic acid.
Assays were generally run for 90 min at room temperature (approximately 23°C) before adding 5 μL of 45 µg/mL antibody in 50 mM Tris (pH 8.5) containing 60 µM Tween-20 and 3 mM EDTA, incubating at least 1 hr at room temperature and reading fluorescence polarization on an EnVision multilabel plate reader. Conditions for the secondary, artifact-detecting assay were the same as those described above with the exception that recombinant Rel Mtb was replaced by 4 µM AMP, simulating the product typically generated by Rel Mtb -catalyzed reactions in the primary assay.
Since compounds used in the HTS were dissolved in DMSO, we next determined the assay sensitivity to DMSO; DMSO up to 5% v/v did not inhibit the assay components.
Conditions for the HTS assay were the same as those described above, but the assay volume was reduced to 6 μL. Assays were performed in 1536-well black polystyrene plates by initially dispensing 3 μL of a 2× enzyme solution (80 nM Rel Mtb in 50 mM Tris pH 8.5, 1 mM DTT, 3 mM Deoxycholic) into wells containing 60 nL of 1mM test compounds in DMSO. Reactions were initiated by addition of 3 μL of 2× substrate solution (3 mM ATP, 1 mM GTP, 2 mM MgCl 2 , 6 nM AMP-Alexa 633 in 50 mM Tris pH 8.5) and then incubated (6µL reaction volume, 10µM compounds, 1% v/v DMSO) for 90 min at room temperature before addition of 3 μL of 3× detection solution (45 µg/mL antibody in 50 mM Tris pH 8.5, 60 µM Tween-20 and 3 mM EDTA). Plates were then incubated for at least 1 h before reading the fluorescence polarization using an EnVision. All additions were made using a Multidrop Combi dispenser (Thermo Fisher Scientific).
Data Analysis and Hit Scoring
The readouts from the EnVision™ multilabel plate reader were integrated with an automated HTS data management system developed internally. This system enables data analysis and quality control 
The calculated Z′ factor greater 0.5, indicating that the assay is suitable for HTS. Therefore, this miniaturized screening assay is suitable for the identification of small-molecule inhibitors of Rel Mtb .
Initially, compounds that altered the overall fluorescence intensity by ≥30% compared with control wells were considered either enhancers or quenchers and were excluded from further analysis. The remaining compounds were evaluated for percent inhibition, which was calculated relative to the assay plate control wells, where
The results from the high throughput screening were further analyzed using using Activity Base (ID Business Solutions Ltd., Surrey, UK); a software package designed to automate the analysis of HTS data to evaluate and score different parameters and identify the most promising compounds from HTS.
Patterns in the distributions of responses in the plates were detected and fixed with an in-house pattern correction algorithm (72).
Consistent with a typical HTS, most compounds were inactive with a distribution of % inhibition values centered on 1.8%. With an average significant statistical inhibition of 24.7% (3 × SD) as threshold (plates were analyzed in daily batches), 12,526 compounds were considered primary hits (0.63% hit rate) and selected for follow-on assays.
To [I] is the concentration of compound, n is the Hill slope, IC 50 is the inflection point concentration. In cases where the highest concentration tested (i.e., 100 μM) did not result in greater than 50% inhibition, the IC 50 was determined as greater than 100 μM. pIC 50 = -logIC 50 , expressing the IC 50 in molar units.
HepG2 cytotoxicity assay
Actively growing HepG2 cells were removed from a T-175 TC flask using 5 mL Eagle's MEM (containing 10 % FBS, 1 % NEAA, 1 % penicillin/streptomycin) and dispersed in the medium by repeated pipetting. Seeding density was checked to ensure that new mono-layers were not more than 50%
confluent at the time of harvesting. Cell suspension was added to 500 mL of the same medium at a final density of 1.2×10 5 cells/mL. This cell suspension was dispensed (25 μL, 3000 cells per well) into 384-well clear-bottom plates using a Multidrop Combi dispenser. Prior to addition of the cell suspension, the screening compounds (250 nL) were pre-dispensed into the plates with an Echo ® liquid handler. Plates were incubated for 48 hr at 37°C, 5% CO 2 . After incubation, plates equilibrated at room temperature for 30 min before proceeding to develop the luminescent signal. The signal developer, CellTiter-Glo ® Reagent, was allowed to equilibrate at room temperature for 30 min and added to the plates (25 μL per well) using a Multidrop Combi dispenser. Plates were left for 10 min at room temperature for stabilization and then read using a ViewLux.
